Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1
  • 2
  • 3
  • 4

RENEURON- stem cell technology (RENE)     

Tonker - 27 Feb 2006 08:22

Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

porky - 24 Jan 2009 13:18 - 45 of 69

Very surprised that this has not been flagged up in the last few days.
Share price rise has been terrific on the news from America that the FDA has authorised stem cell research to go ahead in human tests, and it has also been ok`d by UK authorities to go ahead with their stroke stem cells in human tests.
They are still talking to the FDA, and if this turns positive then the price at the moment will be extremely cheap.

porky - 24 Jan 2009 13:20 - 46 of 69

Alert serviceSite mapSearchHome
Home News & events NewsNews article
ReNeuron gains UK regulatory approval to start ground-breaking clinical trial with stem cell therapy for stroke . 19/01/09
Guildford, UK, 19 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke, the most common form of the condition. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.

In this ground-breaking Phase I trial, the first of its kind using expanded neural stem cells, stroke patients will be treated with ReNeuron's ReN001 stem cell therapy at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board. The Principal Investigator for the trial is Dr. Keith Muir, Senior Lecturer in Neurology at the University of Glasgow. MHRA approval for the trial has been given subject to provision of data both from an ongoing pre-clinical study and from the long term follow-up of trial participants. Following successful completion of the ethics approval process which is currently underway for the trial, patient recruitment is expected to commence in the second quarter of this year.

The trial is designed primarily to test the safety profile of ReN001 in ischaemic stroke patients at a range of cell doses, but a number of efficacy measures will also be evaluated over the course of the trial. The ReN001 cells will be administered by direct injection into the affected region of the brain in a straightforward surgical procedure. Importantly, the nature of the procedure and the characteristics of the ReN001 cells mean that the patients will not require immunosuppression following treatment, thus eliminating the safety risks typically associated with immunosuppression regimens. Patients in the trial will be monitored for one year, with longer term follow-up procedures in place thereafter.

Dr. Keith Muir said:

"Stem cell treatment offers the potential to repair brain tissue lost as a result of stroke. We are very excited at the opportunity to undertake this, the first clinical trial involving neural stem cell therapy in stroke. At this stage, we are primarily seeking to establish the safety and feasibility of this form of treatment, and if successful, we hope that it will lead on to larger studies looking at the effects of the treatment on patient recovery".


Michael Hunt, Chief Executive Officer of ReNeuron, said:

"This regulatory approval marks the first step in the process of testing the safety and potency of our lead ReN001 stroke therapy at a clinical level. It is the most important milestone in ReNeuron's history thus far and also represents a significant development in the wider field as regards the translation of exciting stem cell science into clinical stage therapies. In many ways, ReNeuron has set the regulatory pathway in the UK for cell therapy trials of this type, and we are delighted to have been given the opportunity to move ReN001 into its clinical phase on home territory in the UK"


Enquiries:

ReNeuron

hangon - 28 Jan 2009 21:03 - 47 of 69

IMHO, A lot of hot air, for this Co has had a far greater Punter Interest ( and sp) quite some while ago. In that event they muffed it, destroying many shareholder beliefs that this was the way forward.
So not everyone believes this is the start of something BIG....rather it's the same old hooey, relaunched in another guise.
Today, the sp shows that 4x as many punters want "out" as are willing to pay "spike prices" - - - Oh deary.

Andy - 04 Mar 2009 20:16 - 48 of 69

New article, Click HERE

hangon - 12 Mar 2009 17:26 - 49 of 69

FUND-Raising at 3p/Share

Oh deary, for retail shareholders - this will mean DILUTION, no wonder the sp has fallen so quickly today!

-and the way I read it most of this 3million is already spoken-for by way of repaying Loans . . . . . can someone else explain otherwise?

Joe Say - 12 Mar 2009 19:47 - 50 of 69

No need to explain hangon - you're a PI, and you've been shafted

Don't worry though - no need to lose any sleep as the institutions and the board have all been looked after.

justyi - 12 Mar 2009 20:41 - 51 of 69

This is a dummy company...bail out and don't invest in it.

Joe Say - 13 Mar 2009 19:46 - 52 of 69

Couldn't agree more - the board, its advisors et al are init for themselves, and themselves only.

What posters on other boards are assuming is that this fund raising will be enough - that in itself is highly debatable, but the board has certainly shown how it would like to spread the rewards if and when they do come - certainly ain't gonna be for the PI

Balerboy - 16 Nov 2010 17:48 - 53 of 69

Maybe one to tuck away in the bottom draw with this news, if the research comes good could be worth a bit.,.

dreamcatcher - 23 Jun 2012 07:36 - 54 of 69

Thursday we'll have annual results from ReNeuron , the stem technology researcher. The firm is not in profit yet, but it has high hopes for its ReN001 stem cell therapy for the treatment of the effects of a stroke. It is currently in clinical development.

dreamcatcher - 23 Jun 2012 07:38 - 55 of 69

Chart.aspx?Provider=EODIntra&Code=RENE&S

dreamcatcher - 14 Aug 2012 21:44 - 56 of 69

Stroke Trial Update
RNS
RNS Number : 9276J
ReNeuron Group plc
14 August 2012










14 August 2012
AIM: RENE



ReNeuron Group plc

("ReNeuron" or the "Company")



ReNeuron receives DSMB clearance to progress to higher dose in stem cell clinical trial in stroke patients



First patient treated in this higher dose cohort



Guildford, UK, 14 August 2012: ReNeuron Group plc (AIM: RENE) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.



The Company is pleased to report that the independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advances to the evaluation of a higher dose of ReN001 in the third of four dose cohorts to be treated in the study. In arriving at this recommendation, the DSMB reviewed safety data from the first two dose cohorts of six patients treated with ReN001. Of these patients, two are through 18 month follow-up, one is through 12 month follow-up, one is through 9 month follow-up, one is through 6 month follow-up and one is through three month follow-up. No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date.



The Company is also pleased to report that the first patient in this third dose cohort of three patients has now been successfully treated with ReN001 and discharged from hospital with no acute safety issues arising.



The primary aim of the PISCES study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.



In June of this year, interim data from the PISCES study from the first five patients treated was presented by the Glasgow clinical team at Glasgow at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan. Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.



The PISCES study is the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.



As announced recently, the Company expects that, subject to a continuing lack of cell-related adverse events and affirmative Data Safety Monitoring Board advice, the remaining patients in the PISCES study will have been recruited and treated by early 2013, leaving the Company on track to submit an application for a Phase II clinical study with ReN001 by mid-2013. These remaining patients have already been identified and evaluated as potentially eligible for treatment in the PISCES study, subject to further screening and consenting visits.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



"We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial. This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability."


magicjoe - 18 Sep 2012 11:06 - 57 of 69

Spot the movers 3.10 / 3.20p not any longer

After plenty of 50K sells at offer 3.20p ( order book ) the last one of 750K got the shares moving

Chart.aspx?Provider=Intra&Code=rene&Size

magicjoe - 28 Sep 2012 13:07 - 58 of 69

15 small-cap stocks to buy now
By MoneyWeek Editor John Stepek / Sep 27, 2012

Tom: I’ll stick with the biotech theme. One of the few British players is ReNeuron (LSE: RENE), which basically drills holes into the heads of people who have had a stroke, and injects stem cells to try to revive the part of the brain that has been damaged. It’s early days, but so far the treatment doesn’t seem to do these people any harm and there is early evidence that it does some good.

The interesting thing is that Reneuron’s experience is consistent with what has been reported from stem cell trials elsewhere, notably in America. Stem cell medicine is definitely something to keep an eye on, and is part of the emerging business of regenerative medicine.

http://www.moneyweek.com/investment-advice/share-tips/roundtable-15-small-cap-stocks-that-will-grow-through-recession-60824

Hiram Abif - 22 Oct 2014 10:17 - 59 of 69

Have made several buys recently; latest today. Still not being reflected on trade either by correct quantity or type of transaction.

Looks like MM are using 'automatic stabilizer' trades to hold SP at their desired level. Lots of interest in Stem-cell research and relatively few stockmarket companies trading in such technology.

Recent Cell transplant on spinal nerve has just enabled a paralised man to walk again. This is a massive step in tissue repair and Cell regeneration.

DYOR

HAb

midknight - 22 Oct 2014 11:39 - 60 of 69

I think this may be worth watching or holding for the long term.
Neil Woodford recently bought more and now holds about
20%. News.

Hiram Abif - 23 Oct 2014 09:22 - 61 of 69

Good program on TV last night of a man who had his windpipe replaced and reconstructed with StemCells (over a synthetic frame). Pioneering surgery using Stemcell reconstruction.

He can now breath through his mouth (rather than a hole in his his throat) and speak words for the first time since his accident.

StemCell therapy is now real time in surgery and tissue repair. Ignore at your peril!

DYOR

HAb

Bullshare - 22 Jan 2015 17:31 - 62 of 69

The Innovators & Investors Forum is organised in partnership with Cenkos Securities and Shares.

The event aims to showcase up to 40 pioneering and imaginative technology-led firms, bringing them together with the investment community. It combines both a company expo and an educational conference where delegates learn about a range of investment opportunities. 
 
The event is supported with an extensive conference program, including keynote speakers and company presentations. There is also an opportunity to engage in discussions with exhibitors at their stands.
 
 
Participating companies 
 
 
Abzenaeg solutionsMedaPhorShares
AirPortr ELECOMercia TechnologiesSQS
AJ Bell YouinvestEscher GroupPlastics CapitalStadium Group
APC Technology GroupFlowgroupProxamaTyraTech
Atlantis ResourcesForbidden TechnologiesReNeuron GroupXLMedia
blur GroupImperial InnovationsRightster 
BradyInstemRosslyn Analytics 
Cenkos SecuritiesKBC Advanced TechnologiesSeaEnergy 
Deltex Medical GroupManx TelecomServicePower 
 
More companies to be announced
 
 
Event timings
  
Registration:from 09:00
Conference:09:45 - 17:30
Exhibition:09:00 - 18:00
 
Date:

Tuesday 3rd February 2015

Venue:

Business Design Centre, London N1, 52 Upper Street, Islington, London, N1 0QH

Attendance is free, but spaces are limited. Register now to secure your place!
Cenkos Securities
Cenkos Securities 

Cenkos Securities is an independent specialist securities firm focused on UK small and mid-cap companies.

They aim to be entrepreneurial, whilst seeking to establish long-term relationships with corporate and institutional clients.

Their directors and partners have on average more than 25 years' experience in the UK securities market. They have pioneered and led some of the most successful and innovative transactions in the UK securities market over the last decades.

AJ Bell Youinvest
AJ Bell Youinvest 

AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal.

Shares
Shares 

Shares is the leading weekly publication for the serious private investor. Full of forward facing actionable content, industry leading insight plus honest unbiased content; each week covering areas such as Stocks (Large, Mid or Small Cap), Commodities, Bonds, Funds, Forex, Spreadbetting, CFDs, ISAs, ETFs and personal investing.

Abzena (ABZA:AIM)
Abzena (ABZA:AIM) 

Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics and Antitope.

AirPortr
AirPortr 

Portr is everyone’s personal on-demand porter service, placing less stressful luggage free journeys at travelers’ fingertips.

The service enables passengers to have their luggage delivered between London and it’s airports, same-day, whatever size, wherever they are, whenever needed. They are then free to travel around the city more efficiently, making the most of their time, without their burdensome baggage slowing them down, from only £25.

Combining security, transportation, B2B connectivity and consumer mobile accessibility through technology, Portr has achieved the aviation industry ambition of ‘seamless end-to-end passenger journeys’, delivering innovative solutions, helping airlines and airports improve passenger flows and generate ancillary revenue, while enhancing their travel experiences.  

Having launched at London City Airport in 2014, this year will see Portr’s rollout across a number of London airports.

APC Technology Group (APC:AIM)
APC Technology Group (APC:AIM) 

APC Technology Group PLC provides technologies and services intended to help improve organisational sustainability.  These include sustainability consulting, energy reduction, energy generation, water management and project financing. It is also one of the UK’s leading distributors of specialist electronic components.

Since incorporation in 1982, we have developed outstanding relationships with both specialist manufacturers and our customers, who put significant value on our understanding of their individual business challenges and markets, our technical expertise and the high levels of customer service we provide.

Atlantis Resources (ARL:AIM)
Atlantis Resources (ARL:AIM) 

For more than a decade, Atlantis has been actively involved in the commercialisation of tidal power technology and the development of tidal power projects around the world. Atlantis is striving to become the world’s leading developer of commercial scale tidal power projects and the technologies required to economically deliver tidal current power to the grid for sale and dispatch. Atlantis owns patented technologies covering power generation, turbine deployment and turbine operation and control. The combination of our technology and our track record in successful project origination and development, has created what we believe to be a uniquely commercial force in the marine power industry, able to develop and manage commercial-scale, marine power renewable energy projects globally.

blur Group (BLUR:AIM)
blur Group (BLUR:AIM) 

The way businesses buy and sell services is being revolutionized. blur has torn up the old play book and replaced it with a new one where projects for talented, capable suppliers are won based on merit. We have nearly 50,000 service providers keen to impress you and successfully deliver your project - typically saving you 25%. Businesses like Amazon, Regus, Caterpillar and Argos have changed the way they buy and sell services. They find it easy, fast, fair, with better choice and guaranteed quality. You buy everything else online, why not business services?

Brady (BRY:AIM)
Brady (BRY:AIM) 

Brady Plc is the largest European-headquartered provider of trading and risk management software to the global commodity, energy and recycling markets. Following our listing on AIM, Brady has achieved 50% compound annual growth in revenues over the past five years. It has entered new markets, developed new software solutions, and added global industry leaders as clients. Our growth has resulted from our strategy of combining organic growth with acquisitions, supported by Cenkos, our nomad and broker. Brady is the only UK stock exchange listed company active in the intersection of technology and commodities. We are ranked number one globally in metals, and US recycling, and are the energy Trading and risk Management solution provider with the most energy installations in Europe.

Deltex Medical Group (DEMG:AIM)
Deltex Medical Group (DEMG:AIM) 
Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.
eg solutions (EGS:AIM)
eg solutions (EGS:AIM) 

eg solutions is a back office workforce optimisation software company. eg pioneered this new market space and developed the most complete, purpose built workforce optimisation software for back offices – the only solution that manages work, people and end-to-end processes wherever they are undertaken, anywhere in the world.

Our software is used by leading UK, international and global companies in multiple industry sectors.

Using our forecasting, scheduling, real-time work management and operational analytics capabilities we deliver measureable improvements in service, quality, productivity and regulatory compliance. When supported by our implementation and training services we guarantee return on investment.

ELECO (ELCO:AIM)
ELECO (ELCO:AIM) 

Eleco Plc is an AIM-listed software company with interests based principally in Sweden, Germany and the UK. Eleco develops software tools for the architectural, engineering and construction industries. Eleco is committed to promoting a more sustainable built environment by providing software and services that integrate the construction project delivery process from design through to delivery.

Escher Group (ESCH:AIM)
Escher Group (ESCH:AIM) 

Escher Group Holdings plc is the world leading developer and provider of point of service software for use in the postal industry worldwide. Its core Riposte® software serves 35 national postal services across the world including the United States, Germany, Malaysia, South Africa and Saudi Arabia. The software enables post offices to expand upon their traditional offering, providing new revenue streams, reducing costs and increasing efficiency. The Group has also invested in new products such as Riposte TrEx which is designed to provide a national digital infrastructure linking governments, businesses and citizens via a secure platform. Escher has offices in Dublin, Boston, Singapore, Washington, London and Johannesburg. The Group had an initial public offering in 2011 and is listed on the London Alternative Investment Market (AIM).

Flowgroup (FLOW:AIM)
Flowgroup (FLOW:AIM) 

Flowgroup's patented technology platform will help it dominate the global heating market and the emerging connected home space.

Flowgroup's product range launches with the world's first affordable electricity-generating boiler. This boiler generates low cost, low carbon electricity as it uses gas to heat a home.  It reduces customer electricity bills by 50% and household carbon emissions by up to 20%.  It's designed to become the leading domestic heating technology worldwide with a volume production price close to a standard boiler.

And there's even more to this game-changing boiler.  Couple its generation capability with internet connectivity and an intelligent thermostat and you have the beating heart of the smart, connected home - and a company with global prospects in the most exciting market around.

Forbidden Technologies (FBT:AIM)
Forbidden Technologies (FBT:AIM) 
Forbidden Technologies Plc launched its Forscene cloud video platform in 2004. Used by some of the largest global media players, Forscene is a world leader, having handled 4,000,000 hours of professionally shot source video.
 
During 2013, monthly usage of Forscene rose to over 100 UK TV series. Forbidden capitalised on its successful contract with Google / YouTube by engaging key partners in sports.
 
Gross margins remain in the 85% region.With around 30,000 accounts for its mobile video editing app, Forbidden is positioning to profit from the explosive growth in internet video and mobile devices.
 
In 2013, Forbidden raised over £8m in cash. Forbidden is using this to invest for growth, particularly in the US, where its presence is already being felt.
Imperial Innovations (IVO:AIM)
Imperial Innovations (IVO:AIM) 

Imperial Innovations builds and invests in technology and healthcare companies based on the most promising technologies from our brightest scientists. It is connected with four of the world’s top research universities (Imperial, Cambridge, Oxford and UCL) which between them generate research income of £1.4 billion p.a. A significant technology investor with a portfolio of over 90 companies, Imperial Innovations has invested more than £176.0 million across its portfolio since 2006, and its companies have raised collectively investment of more than £822 million. Innovations invest in the most promising opportunities from whichever technology sector they arise and has built particular expertise in the key sectors of: Therapeutics, Medtech and devices, engineering and materials, and ICT.

Instem (INS.L:AIM)
Instem (INS.L:AIM) 

Instem is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:

- collect, analyse and report complex scientific data;- comply with regulatory reporting requirements;- improve quality, consistency and efficiency of information reporting; and- reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.

KBC Advanced Technologies (KBC:AIM)
KBC Advanced Technologies (KBC:AIM) 
KBC Advanced Technologies plc (KBC.L) is a leading independent consultancy and software company dedicated to the design, operation and management of hydrocarbon processing facilities
worldwide, by empowering our clients with advice and technology to deliver enduring excellence in safety, profitability and environmental performance.
 
Our clients include owners, operators and investors in Oil, Gas, Refining, Petrochemical and relevant Support industries and the technologies at the heart of their operations in Upstream Production and Processing; Mid-stream Gas Handling and Transport; Downstream Refinery Processing, Petrochemicals and supporting Logistics, Financing & Planning. KBC’s client base includes a significant number of national oil companies (NOCs), major international oil companies (IOCs) and independent refiners.
 
KBC was founded in the United Kingdom in 1979 and listed on the London Stock Exchange in 1997. We have 300 staff based in offices across North America, Europe, Middle East, Former Soviet Union and Asia.
Manx Telecom (MANX:AIM)
Manx Telecom (MANX:AIM) 

Manx Telecom is the leading communication solutions provider on the Isle of Man. The Group offers a wide range of fixed line, broadband, mobile and data centre services to businesses, consumers and the public sector on the Isle of Man and provides a growing portfolio of innovative solutions to offshore customers through its Global Solutions division, including Strongest Signal Mobile roaming and Mobile Virtual Network Enabler Services (MVNE). It listed on the AIM section of the London Stock Exchange in February 2014, generated 2013 revenue of £76.0m, +5.0% yoy, and adjusted EBITDA of £27.5m, +11.5% yoy and intends to pay a full year 2014 dividend equivalent to a 7% yield on the IPO price of 142p per share.

MedaPhor (MED:AIM)
MedaPhor (MED:AIM) 

MedaPhor is a global provider of advanced ultrasound education and training for medical professionals. Based in Cardiff in the UK and San Diego in the USA, our aim is simple – to build a world class ultrasound training company that has educational excellence as its core guiding principle.

That core principle is as important now as on the day we started. With products ranging from the very latest in advanced virtual-reality simulation training to hands-on postgraduate courses, we are committed to becoming the world’s leading ultrasound simulation company.

Mercia Technologies (MERC:AIM)
Mercia Technologies (MERC:AIM) 

As an investment business providing funding, hands-on support and accommodation, Mercia's strategy is to provide seed, early stage and development capital from its third party funds under management (via its wholly owned subsidiary Mercia Fund Management) and, at a later stage, provide follow-on capital from its own resources to scale its emerging stars with the goal of realising value for shareholders through an exit over time. Operating nationally with a focus on the Midlands and the North, which have been historically underserved, Mercia has access to enviable sources of deal flow opportunities including partnerships held with nine universities in the region.

Plastics Capital (PLA:AIM)
Plastics Capital (PLA:AIM) 

Plastics Capital is a specialist plastics products manufacturer focused on proprietary products for niche markets. The Group has five factories in the UK, two in China, one in Thailand and sales offices in the USA, Japan, India and China. Plastics Capital was listed on the AIM market in December 2007. 

Currently approximately 40 per cent of sales are exported to over 80 countries worldwide and production is concentrated in the UK where significant engineering know-how and automation underpins the Group’s competitiveness. 

The Group’s corporate strategy is to build shareholder value by continuing to grow its key businesses organically and through value enhancing acquisitions

Proxama (PROX:AIM)
Proxama (PROX:AIM) 

Proxama is a global platform provider of proximity marketing, loyalty and contactless payment solutions on mobile. We provide proximity commerce solutions to financial institutions, media owners, retailers and brands.

Our two technology platforms, TapPoint® and CardGateway®, sit at the heart of our business. TapPoint® delivers proximity engagement and loyalty solutions for retailers, media owners and brands by utilising technologies such as NFC, Bluetooth LE (beacons), geo-fencing and QR codes. CardGateway® is our mobile contactless (NFC) payment platform that enables banks to transition their card portfolio onto mobile, for mobile contactless payments. 

ReNeuron Group (RENE:AIM)
ReNeuron Group (RENE:AIM) 

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead stem cell therapeutic candidate is a therapy for the treatment of patients left disabled by a stroke. Our second application for the CTX cells is for the treatment of critical limb ischaemia. Both treatments are currently in clinical development. Our hRPC stem cell candidate is for the treatment of retinitis pigmentosa, a blindness-causing desease of the retina. This treatment is in late pre-clinical development.

Rightster (RSTR:AIM)
Rightster (RSTR:AIM) 

Rightster is a global b2b video network for distribution, content-sourcing, audience engagement and monetisation. Rightster’s software and services make it simple for sports, fashion, news, entertainment and viral rights holders to maximise the value of their video whether on a licenced, ad-funded, direct to consumer or paid placement basis. Rightster provides an “upload once – commercialise everywhere” solution that extends the reach of live and on-demand video content to web, mobile and connected audiences via clients’ own sites, social channels, portals, platforms, newspapers, magazines and specialist blogs. Thousands of syndication partners are already preconnected, and Rightster’s Multi channel network (MCN) on YouTube consists of 450 channels, regularly featuring in the comScore top partner rankings. Founded by Charlie Muirhead in May 2011, Rightster has since grown to approximately 200 employees across 11 offices in 10 countries.

Rosslyn Analytics (RDT:AIM)
Rosslyn Analytics (RDT:AIM) 

At Rosslyn Analytics, we’re building intelligent businesses.  How?  By enabling our clients to prepare, manage and serve data to their business users.  But, not just any data.  We’re talking smart, enriched, analytics ready data.  With analytics ready data, decisions accelerate.  Teams collaborate.  People innovate.  Businesses captivate.

We’re focused solely on the complex business of data.  And, as business intelligence and analytics make the steady transition to the cloud, we’re taking an evolutionary rather than revolutionary approach.  An approach that bridges the all-important gap between business and data.  Which means data privacy, security and governance is assured. - See more at: http://www.rosslynanalytics.com/company/#sthash.6eCpkQzv.dpuf

SeaEnergy (SEA:AIM)
SeaEnergy (SEA:AIM) 

SeaEnergy PLC (SEA.L) is an innovation-led offshore energy services business.  Since 2012, its focussed strategy has delivered significantly increased turnover, expanded its global reach and is moving towards profitability, in line with expectations.  It comprises:

R2S’s Visual Asset Management, which provides a unique, intuitive and engaging front end for major upstream oil clients’ maintenance management information.  R2S is active in the UK, Gulf of Mexico, Canada and rapidly growing internationally. SeaEnergy’s consultancy focusses on strategic consulting in asset integrity management, management of change and organisational development. Max and Co, our complementary corporate design and communication specialists, combine branding, graphics, 3D animation and web solutions to support clients in communicating complexity.​ SeaEnergy has developed designs and operational concepts for offshore wind farm support vessels which offer significantly improved wind farm economics.  Our ship management team is now managing three vessels and is addressing growth opportunities.
ServicePower (SVR:AIM)
ServicePower (SVR:AIM) 

ServicePower provides connected field services solutions that bring together the customer and the dispatch centre, technician, claims and warranty processes, parts, the contracted workforce, assets, mobility, business intelligence, and social collaboration. ServicePower connects all aspects of the field service value chain through the use of innovative technology that accelerates business efficiency gains and customer satisfaction while reducing costs. ServicePower is uniquely positioned to offer connected field services solutions on one underlying and consistent platform.

SQS (SQS:AIM)
SQS (SQS:AIM) 

The SQS Group (SQS) is the world’s leading specialist in software quality. SQS’ position and expertise as the market leader are the result of over 30 years of successful consultancy. The company’s competitive edge stems mainly from its PractiQ methodology, which is based on many years of project experience and specialist knowledge across a wide range of industries. With over 7,000 completed projects, SQS has a strong customer base, including half of the DAX-30, almost a third of the STOXX-50 and 20 FTSE-100 companies. Our customers include Allianz, Beazley, BP, Centrica, Commerzbank, Daimler, Deutsche Post, Generali, JP Morgan, Meteor, Reuters, UBS and Volkswagen.  

Stadium Group (SDM:AIM)
Stadium Group (SDM:AIM) 

Established over a century ago and headquartered in the UK, Stadium Group plc is an AIM listed, leading electronic technologies group with a turnover of circa £50 million and 800 employees.  Its diverse product portfolio includes power supplies, intelligent interface and displays (Human Machine Interface), M2M (Man-to-Machine) Wireless Connectivity solutions supporting the Internet of Things expansion and integrated electronic manufacturing services (iEMS), which it provides to a broad range of OEMs in the professional electronics market.

Stadium’s products are used in a wide variety of industries including industrial, medical, communications, green technology, automotive, marine, aviation, security and lighting.  It presently operates four manufacturing sites in the UK (Hartlepool, Warrington, Diss and Southampton) a low cost manufacturing operation in China (Dongguan), UK and Asia R&D Centres and commercial offices in the UK, Hong Kong and Australia.

 

TyraTech (TYR:AIM)
TyraTech (TYR:AIM) 

TyraTech, Inc. was established in 2004 to utilize its novel technology to fill the unmet and increasing global demand for effective, safe, and natural pesticide technologies for human and animal health.

TyraTech's products incorporate a unique blend of potent natural active ingredients and are available in a number of markets including consumer, commercial, professional pest control, agriculture, human and animal health, vector control and livestock markets.

TyraTech, Inc. made its Initial Public Offering in June 2007 on the AIM section of the London Stock Exchange, where it trades under two separate common stock share listings (TYR and TYRU). Since going public, TyraTech has established partnerships with market leaders in areas such as human health as well as consumer and commercial pest control operators.

XLMedia (XLM:AIM)
XLMedia (XLM:AIM) 

XLMedia is one of the largest independent online traffic providers to the gambling industry, delivering digital performance marketing services to over 120 operators. It attracts paying users from different online channels and directs them to online gambling operators, typically in return for a revenue share. XLMedia has a scalable platform and clear strategy to support significant growth in both new and existing markets.  With a track record of successful acquisitions it is also well positioned to act as an industry consolidator. In addition, XLMedia has a stated policy of returning at least 50% of retained earnings each year as dividends.

London Stock Exchange
London Stock Exchange 

London Stock Exchange is the world's most international exchange. Nearly 2,500 companies from more than 90 countries are quoted across its markets, with a combined value of £4.4 trillion.

London Stock Exchange's markets include the Main Market - London's flagship venue for equity, debt and exchange traded products, offering businesses access to Europe's most liquid pool of capital - and AIM - the world's leading market for small and growing companies. Since its launch in 1995 AIM has helped 3,500 companies raise £87 billion.

Trading participants access London Stock Exchange markets via a range of secure, low latency interfaces, including the Order book for Retail Bonds (ORB), which since its launch in 2010 has allowed private investors to trade bonds in small denominations, and has helped companies raise over £4 billion.

London Stock Exchange also offers a range of real-time and reference data services, facilitating the trading and reporting of over £1 trillion of securities by 400 members annually.

London Stock Exchange is part of London Stock Exchange Group, which incorporates a range of pan-European trading, technology, post-trade and index businesses.

Miton Group (MGR:AIM)
Miton Group (MGR:AIM) 
Sponsored by:
Cenkos Securities
Shares
AJ Bell Youinvest

js8106455 - 04 Feb 2015 14:47 - 63 of 69

Reneuron - Innovators & Investors Forum

Click here

Bullshare - 11 Jan 2016 16:52 - 64 of 69


MEET THE TECH SUPERSTARS OF TOMORROW


A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Abzena
Advanced Oncotherapy
ANGLE
Brady
Cyan
Eckoh
eg solutions
Flowgroup
Harriman House
Ilika
Instem
Kromek
Lombard Risk
Mercia Technologies 
Mirada
Plastics Capital
Quantum Pharma
ReNeuron
Rosslyn Data Technologies
Selftrade
SHARES
Strat Aero
TP Group
TyraTech
XLMedia


Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London



Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW
  • Page:
  • 1
  • 2
  • 3
  • 4
Register now or login to post to this thread.